Macrophage SLC9A1 Links Endocytic Trafficking to Innate Immune Activation in Myocardial Injury

This study identifies that macrophage SLC9A1 links endocytic trafficking to innate immune activation by promoting the uptake of danger signals and subsequent inflammatory signaling, thereby driving adverse cardiac remodeling after myocardial infarction.

The Gist

The Big Picture: A Heart Attack is a "False Alarm" Party

Imagine your heart is a bustling city. When a heart attack (myocardial infarction) happens, it's like a massive earthquake hitting a neighborhood. Buildings (heart cells) collapse, and debris is everywhere.

Normally, the city's cleanup crew (immune cells called macrophages) rushes in to clear the rubble and fix the damage. This is good! But in this study, the researchers discovered that sometimes the cleanup crew gets too excited. They start screaming at the top of their lungs, causing panic and chaos that actually damages the city further, leading to heart failure.

The paper asks: Why do these cleanup crews get so over-excited, and can we calm them down?

---

The Discovery: The "Vacuum Cleaner" Trap

The researchers found that these heart macrophages have a special habit called macropinocytosis.

• The Analogy: Think of macropinocytosis as a giant, indiscriminate vacuum cleaner. Instead of picking up specific trash, the macrophage opens its mouth wide and sucks in huge volumes of the surrounding fluid, along with everything floating in it.
• The Problem: In a heart attack, that fluid is full of "danger signals" (broken proteins and DNA from dead heart cells). When the macrophage sucks this up, it thinks, "Oh no! We are under attack!" and triggers a massive inflammatory alarm.
• The Result: This alarm causes the heart to remodel (change shape) in a bad way, becoming weak and unable to pump blood effectively.

The Culprit: The "Door Opener" (SLC9A1)

The study identified a specific protein called SLC9A1 as the main reason the vacuum cleaner works so well.

• The Analogy: Imagine SLC9A1 is the electric motor that powers the vacuum cleaner. Without this motor, the vacuum can't suck up the debris.
• The Finding: The researchers found that when they turned off this motor (by deleting the gene in mice), the macrophages couldn't suck up the danger signals as efficiently. Consequently, they didn't get as angry, and the heart healed much better.

The Experiment: Two Ways to Stop the Chaos

The team tested two ways to stop this over-reaction:

1. The Chemical Brake (EIPA): They used a drug called EIPA.

   • Analogy: This is like pouring sand into the vacuum's gears. It jams the machine.
   • Result: The drug stopped the vacuum, calmed the immune system, and saved the hearts of the mice. It also worked against other types of inflammation (like viral or bacterial infections), suggesting it's a broad-spectrum "calm-down" tool.

2. The Genetic Switch (Knockout Mice): They bred mice that couldn't make the SLC9A1 motor in their immune cells.

   • Analogy: This is like removing the electric motor entirely from the vacuum.
   • Result: These mice also had much healthier hearts after a heart attack. Interestingly, removing the motor specifically stopped the macrophages from reacting to nucleic acid danger signals (like viral RNA), but the chemical drug (EIPA) stopped all types of signals. This tells us the drug might be even more powerful than just turning off one specific switch.

The Mechanism: How the Alarm Works

Here is the step-by-step process the paper uncovered:

1. The Suck: The macrophage uses its SLC9A1 motor to vacuum up dangerous debris (like broken DNA/RNA) from the injured heart.
2. The Delivery: This debris is delivered into a special "processing room" inside the cell (the endosome).
3. The Alarm: Inside that room, the debris hits a sensor (TLR3), which screams, "VIRAL ATTACK!" (even if it's just a heart attack).
4. The Overreaction: This triggers a flood of inflammatory chemicals (Interferons) that cause scarring and heart failure.
5. The Fix: If you block the motor (SLC9A1) or jam the vacuum (EIPA), the debris never gets delivered to the sensor. The alarm stays silent, and the heart heals cleanly.

Why This Matters for You

• New Hope: This study suggests that drugs already used for other conditions (like EIPA, which is related to common blood pressure meds) could be repurposed to treat heart attacks.
• Precision Medicine: It shows that the way our immune cells "eat" their environment is a critical control point for inflammation.
• The Takeaway: By understanding how the immune system's "vacuum cleaner" works, we can learn to turn down the volume on the inflammation that kills heart attack survivors, allowing the heart to repair itself without the destructive side effects.

In short: The heart attack creates a mess. The immune system tries to clean it up but accidentally sucks up the "danger signals" that make it panic. By turning off the "motor" (SLC9A1) that powers this suction, we can stop the panic, save the heart, and prevent heart failure.

Technical Summary

1. Problem Statement

Following a myocardial infarction (MI), a robust innate immune response is triggered to clear necrotic debris. However, excessive or prolonged inflammation drives adverse cardiac remodeling and heart failure. While Damage-Associated Molecular Patterns (DAMPs) released from necrotic cardiomyocytes are known to activate Pattern Recognition Receptors (PRRs) in macrophages, the upstream mechanism by which these extracellular danger signals gain intracellular access to engage endosomal sensors (such as TLR3 and TLR4) remains poorly defined. Specifically, the role of macropinocytosis (bulk fluid-phase endocytosis) in this process and the molecular link between membrane ion transport and immune signaling in the injured heart were unknown.

2. Methodology

The study employed a multi-faceted approach combining in vivo mouse models, in vitro cell culture, pharmacological inhibition, and genetic manipulation:

• Animal Models:
  • MI Model: Permanent ligation of the Left Anterior Descending (LAD) coronary artery in C57BL/6J mice.
  • Genetic Knockout: Generation of monocyte- and monocyte-derived macrophage (MDM)-specific Slc9a1 knockout mice (Slc9a1^fl/fl; Ccr2-CreER) using tamoxifen induction.
  • Systemic Challenge Models: Intraperitoneal injection of Lipopolysaccharide (LPS, TLR4 ligand) and Poly(I:C) (TLR3 ligand) to simulate systemic inflammation.
• Pharmacological Interventions:
  • Use of EIPA (5-(N-ethyl-N-isopropyl)amiloride), a macropinocytosis inhibitor and Na⁺/H⁺ exchanger (NHE) blocker.
  • Use of NPS-2143, a structurally distinct macropinocytosis inhibitor, to confirm mechanism.
• Cellular Assays:
  • Macropinocytosis Quantification: Uptake of FITC-Dextran (70 kDa) and DQ-Red BSA (self-quenched substrate) in Bone Marrow-Derived Macrophages (BMDMs) and in vivo infarct tissue.
  • Stimulation: BMDMs stimulated with mDAMP (myocardial DAMP preparation derived from infarcted heart mitochondria), LPS, or Poly(I:C).
  • Knockdown: siRNA-mediated silencing of Slc9a1 in BMDMs.
  • Uptake Imaging: Rhodamine-labeled Poly(I:C) uptake assays and EEA1 (early endosome marker) staining via confocal microscopy.
• Omics and Molecular Analysis:
  • scRNA-seq: Single-cell RNA sequencing of cardiac macrophages isolated from MI tissue to profile transcriptional changes.
  • Bulk RNA-seq & qRT-PCR: Analysis of inflammatory cytokines and Interferon-Stimulated Genes (ISGs).
  • Western Blot: Assessment of signaling pathways (NF-κB, ERK, mTORC1, TBK1, IRF3).
  • Proteomics: Comparative analysis of mDAMP vs. interstitial fluid from infarct tissue.

3. Key Contributions

• Identification of Macropinocytosis as a Driver: The study establishes that macropinocytosis is robustly activated in infarct-associated macrophages and serves as a critical mechanism for internalizing extracellular DAMPs.
• Discovery of SLC9A1's Non-Canonical Role: It reveals that SLC9A1 (NHE1), traditionally known for pH regulation, is the predominant Na⁺/H⁺ exchanger in macrophages and acts as a crucial regulator of endocytic trafficking and innate immune signaling.
• Mechanistic Link: The paper defines a direct mechanistic link where SLC9A1 facilitates the endocytic uptake of nucleic acid ligands (like Poly(I:C)), thereby enabling their delivery to endosomal TLR3 and subsequent Type I Interferon (IFN) activation.
• Therapeutic Potential: It demonstrates that targeting SLC9A1-dependent trafficking (via EIPA or genetic deletion) attenuates maladaptive inflammation and improves cardiac outcomes, suggesting a new therapeutic avenue for ischemic heart disease and systemic inflammation.

4. Key Results

A. Macropinocytosis is Active in MI Macrophages and Drives Injury

• Observation: Macrophages in the infarct zone exhibited high levels of macropinocytosis (confirmed by FITC-Dextran and DQ-Red BSA uptake), far exceeding that of neutrophils or lymphocytes.
• Intervention: Pharmacologic inhibition of macropinocytosis with EIPA significantly improved cardiac function (increased EF/FS), reduced left ventricular dilation, and decreased scar size/remodeling post-MI.
• Mechanism: EIPA blocked the uptake of DAMPs and suppressed downstream inflammatory signaling (NF-κB, ERK, mTORC1).

B. mDAMPs Activate TLR Pathways via Macropinocytosis

• mDAMP Characterization: A preparation of myocardial DAMPs (mDAMP) recapitulated the proteomic profile of infarct interstitial fluid.
• Signaling: mDAMP stimulation triggered rapid activation of NF-κB, ERK, and mTORC1, and robustly induced Il1b, Cxcl10, and Il6.
• Inhibition: Both EIPA and NPS abolished mDAMP-induced cytokine expression, confirming that macropinocytosis is required for DAMP sensing.

C. SLC9A1 is Essential for Macrophage Inflammatory Responses

• Genetic Validation: Conditional deletion of Slc9a1 in monocytes/MDMs (MacΔSlc9a1) phenocopied the protective effects of EIPA, reducing cardiac remodeling and improving function post-MI.
• Transcriptomics: scRNA-seq revealed that Slc9a1 deletion led to a profound suppression of Interferon-Stimulated Genes (ISGs) (e.g., Isg15, Ifit1, Cxcl10) across macrophage clusters, particularly in the newly recruited monocyte-derived subset (Mac3).
• Pathway Specificity:
  • TLR3 (Poly(I:C)): Slc9a1 deletion significantly reduced Poly(I:C)-induced ISG expression and TBK1/IRF3 phosphorylation.
  • TLR4 (LPS): While EIPA inhibited LPS responses, Slc9a1 deletion had a more limited effect on LPS signaling, suggesting EIPA may have broader targets or that TLR4 signaling is less dependent on SLC9A1-mediated uptake than TLR3.

D. Mechanism: SLC9A1 Facilitates Endocytic Uptake

• Ligand Internalization: Slc9a1 knockdown reduced the cellular uptake of Rhodamine-Poly(I:C) and diminished early endosome (EEA1) formation upon stimulation.
• Selectivity: The defect was specific to endosome-dependent signaling. When Poly(I:C) was directly transfected into the cytosol (bypassing endocytosis), Slc9a1 deletion did not impair TBK1/IRF3 activation or ISG expression. This confirms SLC9A1's role is in the uptake/trafficking step, not the cytosolic sensor itself.

E. Translational Relevance

• EIPA treatment attenuated cardiac inflammation and dysfunction induced by systemic LPS and Poly(I:C) challenges, even in the absence of massive immune cell recruitment, suggesting direct effects on resident cardiac cells or rapid modulation of circulating monocytes.

5. Significance

• Novel Mechanism: This study redefines the role of SLC9A1 from a simple pH regulator to a critical gatekeeper of innate immune sensing in macrophages. It bridges the gap between membrane ion transport, actin-dependent endocytosis, and inflammatory signaling.
• Therapeutic Insight: The findings suggest that macropinocytosis is a druggable target for limiting maladaptive inflammation in myocardial infarction.
• Drug Repurposing: The use of EIPA (an amiloride derivative with existing clinical safety data) highlights a potential strategy to treat ischemic heart disease and sepsis-induced cardiomyopathy by dampening excessive innate immune activation without necessarily requiring isoform-specific genetic engineering.
• Distinction between Genetic and Pharmacologic: The study notes a divergence between genetic Slc9a1 deletion (selective for TLR3/endocytic uptake) and pharmacologic EIPA inhibition (broad suppression of TLR3 and TLR4), underscoring the complexity of targeting membrane trafficking pathways.

In conclusion, the paper identifies macrophage SLC9A1 as a previously unrecognized regulator that links membrane ion transport to the endocytic uptake of danger signals, thereby amplifying Type I Interferon responses and driving adverse remodeling after myocardial injury.